COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1793 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-05-18

Study Completion Date

2022-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The classic myeloproliferative neoplasias (MNP), including polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) or secondary to PV or ET, are among the most frequent of malignant hemopathies, with overall prevalence estimated at around 10,000 patients followed in France. Due to the median age of patients around 65, the frequency of cardiovascular complications of these thrombogenic diseases and the impact of cytoreductive treatments on immune cells, these patients are considered to be at risk of developing forms severe of COVID-19. This study will assess the impact of MNPs on the risk of developing a severe form of COVID-19, identify new risk factors linked to the disease as well as the impact of treatments for MNPs according to their pharmacological class.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19

NCT04452604

Acute Myeloblastic Leukemia Acute Lymphoblastic Leukemia SARS-CoV-2

COMPLETED

Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

NCT01423058

Primary Myelofibrosis Post-Polycythemia Vera Post-Essential Thrombocythemia Myelofibrosis

COMPLETED PHASE1/PHASE2

Characteristics of Patients With Philadelphia Negative Myeloproliferative Neoplasms at Assiut University Hospital

NCT05401864

Philadelphia Negative Myeloproliferative Neoplasms

UNKNOWN

Clinical Characteristics of Patients With Leukemia and COVID-19

NCT04745416

Leukemia, Acute Covid19 Leukemia, Lymphoblastic

COMPLETED

Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

NCT02124746

Primary Myelofibrosis Post-Polycythemia Vera Myelofibrosis Post-Essential Thrombocythemia Myelofibrosis +2 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is a descriptive, prospective epidemiological study using retrospective patient data, multicenter, non-interventional, carried out in FIM (French Intergroup of Myeloproliferative syndromes) / FILO (French Innovative Leukemia Organization) centers.

This is an exploratory descriptive study in order to put in place as soon as possible a possible strategy for the protection of patients most at risk.

The study will include all consecutive patients with MNP according to the WHO (World Health Organization) classification seen in consultation or teleconsultation over the duration of the study, whether or not they have had a COVID-19 infection.

The collection of clinical data, treatment regimens and survival and death data will be carried out by the investigator or a member of his medical team, after delivering an information note to the patient informing him of the computerized processing of his data, subject to the patient's non-objection.

The diagnosis of asymptomatic COVID 19 will be made on the presence of a positive serology and on the absence of clinical signs on questioning.

The presence of a symptomatic COVID 19 infection will be posed on the presence of clinical signs +/- CT as identified by the practitioner who treated the patient and confirmed or not by a positive PCR and / or a positive serology.

Data collected:

* Socio-demographic data (gender, date of birth)
* Description of hemopathy and its treatment
* Description of COVID-19 infection and its management
* Biological data: blood count, specific COVID-19 test results if available (PCR, serology).
* History, comorbidities
* Evolution of COVID-19 infection and possible specific treatment

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myeloproliferative Neoplasm COVID-19 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with PV, ET, PMF or MF secondary to PV or ET diagnosed before the COVID-19 pandemic
* Seen in consultation or teleconsultation from May 2020 or deceased if the investigator became aware of this death during the study period